Recent advances in non-toxic quantum dots and their biomedical applications

Publication date: Available online 21 February 2020Source: Progress in Natural Science: Materials InternationalAuthor(s): Chunyan Zhu, Zhao Chen, Shuai Gao, Ban Leng Goh, Ismail Bin Samsudin, Kai Wen Lwe, Yunlong Wu, Caisheng Wu, Xiaodi SuAbstractQuantum dots (QDs) with unique quantum confinement effect and electro-optical properties are attractive for biomedical applications. Toxic effects of traditional semiconductor QDs made of heavy metal ions have serious safety concerns for their undesired environmental or healthy impact. Recent reports on core-shell structure modification of QDs by using biocompatible ligands or polymers is one way to be effectively minimizing toxicity effects of traditional QDs. Furthermore, designs of heave metal-free and metal-free QDs formulations are more promising alternatives, due to the non-toxic and eco-friendly nature of the starting materials. In article, we will review the recent designs of non-toxic or less toxic QDs, including carbon-based, biomolecules-based, silicon-based, and ternary I-III-VI QDs, and their biological applications (bio-imaging, drug delivery, gene therapy and immunoassay).Graphical abstract
Source: Progress in Natural Science: Materials International - Category: Materials Science Source Type: research

Related Links:

ElevateBio, the local cell and gene therapy holding company created by former executives from Alexion Pharmaceuticals and bluebird bio, is set to move six drugs to clinical trials after raising new financing. ElevateBio aims to create and invest in companies that are developing treatments that directly affect a person’s cells and genes. It was launched last year by former bluebird bio (Nasdaq: BLUE) chief scientific officer Mitchell Finer, and former Alexion Pharmaceuticals (Nasdaq: ALXN) CEO…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
In conclusion, we reveal that targetingmir128-3p mitigates myocardial insulin resistance, thereafter slowing down the progression of heart failure post-ischemia.
Source: eLife - Category: Biomedical Science Tags: Biochemistry and Chemical Biology Cell Biology Source Type: research
by Ziying Hu, Shuai Wang, Chengdong Zhang, Ning Gao, Miaomiao Li, Deqian Wang, Daqi Wang, Dong Liu, Huihui Liu, Sang-Ging Ong, Hongyan Wang, Yongming Wang Compact CRISPR/Cas9 systems that can be packaged into an adeno-associated virus (AAV) hold great promise for gene therapy. Unfortunately, currently available small Cas9 nucleases either display low activity or require a long protospacer adjacent motif (PAM) sequence, limiting their extensive appli cations. Here, we screened a panel of Cas9 nucleases and identified a small Cas9 ortholog fromStaphylococcus auricularis (SauriCas9), which recognizes a simple NNGG PAM, displ...
Source: PLoS Biology: Archived Table of Contents - Category: Biology Authors: Source Type: research
This study, for the first time, shows that transplantation of non-autologous mitochondria from healthy skeletal muscle cells into normal cardiomyocytes leads to short-term improvement of bioenergetics indicating "supercharged" state. However, over time these improved effects disappear, which suggests transplantation of mitochondria may have a potential application in settings where there is an acute stress. Outlining Some of the Science Behind Partial Reprogramming at Tur...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Shahverdi M, Amini R, Amri J, Karami H Abstract BACKGROUND: Despite the dramatic efficacy of ABT-737, a large percentage of cancer cells ultimately become resistance to this drug. Evidences show that over-expression of Mcl-1 is linked to ABT-737 resistance in NSCLC cells. The aim of this study was to investigate the effect of miRNA-101 on Mcl-1 expression and sensitivity of the A549 NSCLC cells to ABT-737. METHODS: After miRNA-101 transfection, the Mcl-1 mRNA expression levels were quantified by RT-qPCR. Trypan blue staining was used to explore the effect of miRNA-101 on cell growth. The cytotoxic effe...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Zolgensma is a gene therapy that addresses the genetic root cause of spinal muscular atrophy by replacing the defective or missing SMN1 gene to halt disease progression.International Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Swiss drugmaker Novartis on Friday won a key European recommendation for its gene therapy Zolgensma against spinal muscular atrophy (SMA), clearing a hurdle for $2.1 million per patient treatment for approval in Europe within months.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
A committee of the European health regulator on Friday recommended approving Swiss drugmaker Novartis AG's gene therapy Zolgensma for a muscle wasting disease in babies and young children.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News CDC’s COVID-19 Guidance for Dental Settings  Dental health care personnel can find COVID-19-related information on the CDC’s Division of Oral Health website, which offers guidance and resources for clinics and health care facilities and recommen...
Source: NIDCR Science News - Category: Dentistry Source Type: news
(Mary Ann Liebert, Inc./Genetic Engineering News) Gene therapy investigators can greatly benefit from the resources and services provided by the National Gene Vector Biorepository (NGVB), housed at the Indiana University School of Medicine.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Environmental Health | Gene Therapy | Genetics | Materials Science | Science | Toxicology